| Q38913907 | 5-Alpha-Reductase Inhibitors and Combination Therapy |
| Q36342157 | 5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec. |
| Q22252970 | 5-alpha-reductase inhibitors for prostate cancer prevention |
| Q36892851 | 5alpha-reductase inhibition for men with enlarged prostate |
| Q34466639 | 5alpha-reductase inhibitors: what role should they play? |
| Q28367575 | A 6-month large-scale study into the safety of tamsulosin |
| Q33154283 | A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. |
| Q80297824 | A Primary Care Physician's Perspective on Benign Prostatic Hyperplasia |
| Q38784920 | A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-analysis |
| Q24794338 | A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy |
| Q44897657 | A Trial Study: The Effect of Low Dose Human Chorionic Gonadotropin on the Symptoms of Benign Prostatic Hyperplasia |
| Q37281116 | A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia |
| Q77108790 | A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia |
| Q48273768 | A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride |
| Q36852683 | A review of combination therapy in patients with benign prostatic hyperplasia |
| Q41733328 | A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia |
| Q33709639 | A systematic review of the clinical efficacy and effectiveness of the holmium:YAG laser in urology |
| Q80297594 | AUA Guidelines and Their Impact on the Management of BPH: An Update |
| Q39467122 | Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. |
| Q35681738 | Acute urinary retention: a review of the aetiology and management |
| Q36576011 | Acute urinary retention: who is at risk and how best to manage it? |
| Q36916873 | Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia |
| Q28069186 | Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review |
| Q34563071 | Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia |
| Q34073296 | Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate |
| Q34655716 | Alpha blockers for the treatment of benign prostatic hyperplasia. |
| Q34080452 | Alpha blockers: are all created equal? |
| Q36371582 | Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice |
| Q74605813 | Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist |
| Q38913905 | Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia |
| Q41875055 | Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea |
| Q46817448 | Analysis of the scientific evidence of the combination therapy in benign prostatic hyperplasia |
| Q34111603 | Androgen deprivation therapy for prostate cancer-review of indications in 2010 |
| Q36298863 | Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer |
| Q38097574 | Androgen receptor roles in the development of benign prostate hyperplasia |
| Q37092262 | Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia |
| Q63966029 | Benign prostatic hyperplasia |
| Q77112270 | Benign prostatic hyperplasia |
| Q93501252 | Benign prostatic hyperplasia |
| Q33741424 | Benign prostatic hyperplasia (the aging prostate). |
| Q34003918 | Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS) |
| Q36737065 | Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management |
| Q50624029 | Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. |
| Q41476462 | Benign prostatic hyperplasia in elderly men. What are the special issues in treatment? |
| Q74425024 | Benign prostatic hyperplasia in older men |
| Q36859820 | Benign prostatic hyperplasia. Practical treatment guidelines |
| Q36300022 | Benign prostatic hyperplasia: an insight into current investigational medical therapies |
| Q33545587 | Benign prostatic hyperplasia: an overview |
| Q34421491 | Benign prostatic hyperplasia: diagnosis and treatment guideline. |
| Q40286733 | Benign prostatic hyperplasia: does prostate size matter? |
| Q56656567 | Benigne Prostatahyperplasie |
| Q80296164 | Best of the 2002 AUA Annual Meeting: Highlights of the 2002 Annual Meeting of the American Urological Association May 25-30, 2002, Orlando, FL |
| Q43823722 | Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride |
| Q53123387 | Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. |
| Q38008697 | Botulinum toxin injection for lower urinary tract dysfunction |
| Q33443661 | Changes in urination according to the sound of running water using a mobile phone application |
| Q35720576 | Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia |
| Q30985147 | Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations |
| Q52076300 | Clinical efficacy of a new 30-min algorithm for transurethral microwave thermotherapy: initial results. |
| Q78024613 | Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements and uroflowmetry |
| Q80297424 | Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia |
| Q37994725 | Combination pharmacological therapies for the management of benign prostatic hyperplasia |
| Q36329271 | Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options |
| Q45224634 | Combination therapy in benign prostatic hyperplasia (BPH) |
| Q46199971 | Combination therapy of benign prostate syndrome/lower urinary tract symptoms |
| Q31912887 | Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia |
| Q37790387 | Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia |
| Q53333416 | Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. |
| Q31149371 | Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data |
| Q46612592 | Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction |
| Q44035128 | Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study |
| Q80297582 | Comparison of clinical trials with finasteride and dutasteride |
| Q53152507 | Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). |
| Q53343212 | Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. |
| Q45335136 | Comparison of prostate size in university and Veterans Affairs Health Care System patients with negative prostate biopsies |
| Q53125192 | Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. |
| Q41465608 | Conservative non-instrumental treatment of benign prostatic hyperplasia |
| Q44846255 | Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia |
| Q74553189 | Controversies in the management of lower urinary tract symptoms: an overview |
| Q39443380 | Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound |
| Q58590965 | Cost Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience |
| Q73290311 | Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods |
| Q73290315 | Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results |
| Q85201624 | Cost–effectiveness of prostate cancer chemoprevention among high-risk men |
| Q24649617 | Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations |
| Q38103891 | Current pharmacological treatment options for male lower urinary tract symptoms |
| Q33602452 | Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. |
| Q31137087 | Current treatment options for benign prostatic hyperplasia and their impact on sexual function |
| Q32064218 | Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia |
| Q34752909 | Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians |
| Q39486369 | Differences in prostate size between patients from University and Veterans Affairs Medical Center populations |
| Q41592575 | Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin |
| Q43698829 | Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia |
| Q51995938 | Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study. |
| Q31913030 | Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? |
| Q47907594 | Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? |
| Q56995074 | Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH |
| Q44406188 | Doxazosin and finasteride alone or in combination: the PREDICT study |
| Q39454135 | Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months |
| Q36590479 | Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia |
| Q36434305 | Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia |
| Q38468579 | Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia |
| Q39243100 | Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin |
| Q34218260 | Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting |
| Q34313221 | Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation |
| Q36417140 | Effects of alpha(1)-adrenoceptor antagonists on male sexual function |
| Q51450532 | Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. |
| Q35042953 | Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate |
| Q74293684 | Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up |
| Q44118776 | Effects of finasteride on vascular endothelial growth factor |
| Q33961645 | Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia |
| Q33956422 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial |
| Q44297418 | Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial |
| Q43754275 | Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia |
| Q34659701 | Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms. |
| Q35042910 | Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial |
| Q53570192 | Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. |
| Q39435683 | Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer |
| Q34565171 | Emerging drug therapies for benign prostatic hyperplasia |
| Q37743490 | Emerging drugs for the treatment of benign prostatic obstruction. |
| Q37639596 | Established medical therapy for benign prostatic hyperplasia |
| Q39344228 | Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia |
| Q41652645 | Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial |
| Q21245273 | Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials |
| Q36379355 | Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it |
| Q34171403 | Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy |
| Q37253842 | Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer |
| Q80298296 | Factors in Predicting Failure with Medical Therapy for BPH |
| Q36847310 | Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia |
| Q24234464 | Finasteride for benign prostatic hyperplasia |
| Q24795452 | Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials |
| Q37261063 | Finasteride in the treatment of patients with benign prostatic hyperplasia: a review |
| Q39020100 | Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. |
| Q33343320 | Finasteride-induced thrombocytopenia |
| Q30947980 | Finasteride: 10 years of clinical use. Systematic review of the literature |
| Q33611942 | Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia |
| Q36482570 | First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment? |
| Q26770425 | Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia |
| Q77304973 | Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins |
| Q33147830 | Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons |
| Q44483005 | Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. |
| Q87791195 | Impact of Formulation on the Pharmacokinetic Profile of Dutasteride |
| Q38239520 | Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function. |
| Q34531114 | Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. |
| Q33657855 | Impact of drug therapy on benign prostatic hyperplasia-specific quality of life |
| Q30011093 | Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia |
| Q34707738 | Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs |
| Q53500239 | Influence of sociodemographic and health status variables on the American Urological Association symptom scores in patients with lower urinary tract symptoms. |
| Q33610894 | Is transurethral resection of the prostate still justified? |
| Q34080443 | LUTS, ED, QOL: alphabet soup or real concerns to aging men? |
| Q80297787 | Landmark studies impacting the medical management of benign prostatic hyperplasia |
| Q93811613 | Landmark studies impacting the medical management of benign prostatic hyperplasia |
| Q87134221 | Landmarks in BPH--from aetiology to medical and surgical management |
| Q38063330 | Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action |
| Q36158226 | Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. |
| Q42542039 | Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group |
| Q42677615 | Long-term implications of medical therapy on benign prostatic hyperplasia end points |
| Q44573192 | Long-term results of medical treatment in benign prostatic hyperplasia |
| Q39407346 | Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study |
| Q42675109 | Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia |
| Q35225398 | Lower urinary tract symptoms in men. |
| Q35212498 | Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life |
| Q35212504 | Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment |
| Q32155122 | Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia |
| Q36511604 | Management of bladder, prostatic and pelvic floor disorders |
| Q84757653 | Management of urinary incontinence |
| Q37523227 | Measurement of benign prostatic hyperplasia treatment effects on male sexual function |
| Q35839585 | Mechanistic insights into the role of alpha1adrenergic receptors in lower urinary tract symptoms. |
| Q35204840 | Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life |
| Q37192948 | Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily |
| Q81384288 | Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense? |
| Q33588534 | Medical treatment of benign prostatic hyperplasia |
| Q84723780 | Medical treatment of benign prostatic hyperplasia |
| Q28576448 | Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats |
| Q74544871 | Meta-analysis of randomized clinical trials of finasteride |
| Q43801239 | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia |
| Q34491450 | Molecular action of androgen in the normal and neoplastic prostate |
| Q36243775 | Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia |
| Q41030916 | New Visual Prostate Symptom Score versus International Prostate Symptom Score in Men with Lower Urinary Tract Symptoms: A Prospective Comparision in Indian Rural Population |
| Q58269335 | Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice |
| Q44598735 | Obstructive lower urinary tract symptoms correlate with erectile dysfunction |
| Q35919193 | Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH) |
| Q82704577 | Overactive bladder and outlet obstruction in men |
| Q35685846 | PSA measurement in the treatment of BPH. |
| Q39631908 | PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study |
| Q80298245 | Pathophysiology of benign prostatic hyperplasia in the aging male population |
| Q82755977 | Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease |
| Q80298289 | Pathophysiology of lower urinary tract symptoms in the aging male population |
| Q37406930 | Pharmacological effects of saw palmetto extract in the lower urinary tract |
| Q35871178 | Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician |
| Q74605816 | Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group |
| Q44982532 | Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications |
| Q38067480 | Physiology, pathology and pharmacology of the male reproductive system |
| Q34707746 | Phytotherapeutic agents in the treatment of benign prostatic hyperplasia |
| Q74541150 | Phytotherapy for benign prostatic hyperplasia |
| Q33591029 | Phytotherapy in the treatment of benign prostatic hyperplasia: an update |
| Q38573073 | Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials. |
| Q44744516 | Propecia-associated bilateral cataract |
| Q53159440 | Prospective comparative study of endoscopic management of bladder lithiasis: is prostate surgery a necessary adjunct? |
| Q81655666 | Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates |
| Q41471860 | Prostate disease in older men: 1. Benign hyperplasia |
| Q43846870 | Protein kinase C and the sub-sensitivity and sub-reactivity of the diabetic rat prostate gland to noradrenaline |
| Q34520502 | Quality of life and alpha-blocker therapy: an important consideration for both the patient and the physician |
| Q35803156 | Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics |
| Q31037789 | Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy |
| Q33791941 | Recent advances. General medicine |
| Q56940324 | Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia |
| Q39392083 | Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study |
| Q35328005 | Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability |
| Q33146637 | Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects |
| Q34254296 | Role of 5α-reductase inhibitors in benign prostatic diseases |
| Q80297600 | Role of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPH |
| Q35157640 | Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia |
| Q80296383 | Saw Palmetto Berry as a Treatment for BPH |
| Q74605848 | Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms |
| Q35877386 | Saw palmetto and benign prostatic hyperplasia |
| Q42828508 | Saw palmetto ethanol extract inhibits adipocyte differentiation |
| Q36206605 | Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia |
| Q41217704 | Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia |
| Q24202555 | Serenoa repens for benign prostatic hyperplasia |
| Q24241144 | Serenoa repens for benign prostatic hyperplasia |
| Q56995052 | Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo |
| Q39490244 | Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia |
| Q38913934 | Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments. |
| Q38814349 | Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis |
| Q35040967 | Sexual function in patients treated for benign prostatic hyperplasia |
| Q84219711 | Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia |
| Q42250171 | Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia |
| Q82536874 | Should combination therapy be standard for benign prostatic hyperplasia? |
| Q35982334 | State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. |
| Q42167871 | Stroke associated with alpha blocker therapy for benign prostatic hypertrophy |
| Q39396121 | Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial |
| Q34163024 | Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network |
| Q36174655 | Symptom scores: mumbo jumbo or meaningful measures? |
| Q28370531 | Tamsulosin for the treatment of benign prostatic hypertrophy |
| Q34597840 | Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms |
| Q34492626 | Tamsulosin: an update of its role in the management of lower urinary tract symptoms |
| Q31866840 | Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months |
| Q37883012 | Targeting 5α-reductase for prostate cancer prevention and treatment |
| Q24234560 | Terazosin for benign prostatic hyperplasia |
| Q30880131 | Terazosin for benign prostatic hyperplasia. |
| Q42539019 | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. |
| Q42573911 | Terazosin treatment induces caspase-3 expression in the rat ventral prostate |
| Q39484078 | The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia |
| Q45260612 | The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia |
| Q38364582 | The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin |
| Q33928886 | The economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia |
| Q36115230 | The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels |
| Q33534833 | The medical management of lower urinary tract symptoms and benign prostatic hyperplasia |
| Q80297793 | The medical therapy of prostatic symptoms study: what will we learn? |
| Q93811589 | The medical therapy of prostatic symptoms study: what will we learn? |
| Q27025700 | The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors |
| Q30945262 | The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data |
| Q34877827 | The role of combination medical therapy in benign prostatic hyperplasia |
| Q35185800 | The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia |
| Q79456677 | The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia |
| Q34451466 | The role of plant-derived drugs and herbal medicines in healthcare |
| Q74293691 | The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring |
| Q55019942 | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. |
| Q35839589 | The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia |
| Q37323301 | The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia |
| Q46077661 | Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy |
| Q37423744 | Therapeutic options in the treatment of benign prostatic hyperplasia |
| Q45370003 | Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates |
| Q39443245 | Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? |
| Q33154414 | Treatment of benign prostatic hyperplasia in patients with cardiovascular disease |
| Q39458047 | Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective |
| Q44132860 | Treatment of benign prostatic hypertrophy: present situation and future prospects |
| Q81156827 | Treatment of bladder stones without associated prostate surgery: results of a prospective study |
| Q36116528 | Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression |
| Q78704297 | Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France |
| Q33821256 | Treatment of nocturia in the elderly |
| Q78050429 | Treatment options for benign prostatic hyperplasia |
| Q49124632 | Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study compa |
| Q51925439 | Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. |
| Q38052091 | Update on the sexual impact of treatment for benign prostatic hyperplasia |
| Q38116465 | Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. |
| Q74425020 | Urinary incontinence |
| Q74600043 | Urinary incontinence in the elderly. Causes and treatment options |
| Q77524737 | Urinary incontinence in the elderly. Drug treatment options |
| Q33741435 | Urinary incontinence in the older man. |
| Q44665630 | Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder |
| Q34604979 | Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline |
| Q36576034 | Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease |
| Q39752829 | Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies |
| Q39274525 | Use of meta-analytic results to facilitate shared decision making |
| Q36181722 | Various treatment options for benign prostatic hyperplasia: A current update |
| Q63966058 | Watchful waiting or drug therapy for benign prostatic hyperplasia? |
| Q36479422 | What is the best medical treatment for benign prostate hyperplasia? |
| Q52365475 | [Benign prostate hyperplasia]. |
| Q80526451 | [Contemporary medical management of the benign prostatic syndrome] |
| Q73945385 | [Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia] |
| Q86032050 | [Importance of adrenoceptor blockers and alpha reductase inhibitors : Monotherapy for treatment of benign prostate syndrome] |
| Q83335639 | [Medical combination therapy in LUTS suggestive of BPH] |
| Q84561425 | [Medical therapy of lower urinary tract symptoms [corrected]] |
| Q81273951 | [Potential sexual consequences associated with benign prostatic hyperplasia and its treatments] |
| Q73830065 | [Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin] |
| Q86590305 | [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia] |
| Q84564028 | [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)] |
| Q83498325 | [Treatment of LUTS in BPS. When and when not to administer pills?] |
| Q42535889 | α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results |